Toggle

Three drugs, dexamethasone, leflunomide and pomalidomide to treat multiple myeloma that has come back (relapsed) or has not gotten better with treatment (refractory)

Print

18 and older

Phase 2

8 Locations

NCT04508790

Clinical Trial Goal


To find out if the combination of dexamethasone, leflunomide and pomalidomide is safe and works well to treat multiple myeloma that has relapsed or is refractory

You may be able to join this trial if you:


  • Are 18 years old or older
  • Have multiple myeloma that has relapsed or is refractory
  • Have been treated with bortezomib, carfilzomib, ixazomib or another proteasome inhibitor. Your doctor can tell you this
  • Have been treated with lenalidomide, pomalidomide, thalidomide or another immunomodulatory drug. Your doctor can tell you this
  • Do not have myeloma that is refractory to treatment with pomalidomide. Your doctor can tell you this
  • Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT)
  • Agree to have other standard tests done to see if you can be in the clinical trial

Trial Details


Leflunomide is a drug that slows down the immune system and reduces inflammation.
Pomalidomide is a drug that blocks the growth of cancer cells.

You’ll get:
  • Dexamethasone – A pill that you take by mouth 1 time each week 
  • Leflunomide – A pill that you take by mouth 1 time each day
  • Pomalidomide – A pill that you take by mouth 1 time each day for the first three weeks of each month

You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have scans and biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.  

The Food and Drug Administration (FDA) has approved the combination of dexamethasone and pomalidomide to treat multiple myeloma that has relapsed or is refractory. The FDA has approved leflunomide to treat an inflammatory condition called rheumatoid arthritis. Using the combination of dexamethasone, leflunomide and pomalidomide to treat multiple myeloma that has relapsed or is refractory is new and unproven.

Locations

City of Hope at Antelope ValleyRECRUITING

Lancaster, California
Michael Rosenzweig, 6262184673, mrosenzweig@coh.org

City of Hope at Long Beach ElmRECRUITING

Long Beach, California
Michael Rosenzweig, 6262184673, mrosenzweig@coh.org

City of Hope at Newport Beach Fashion IslandRECRUITING

Newport Beach, California
Michael Rosenzweig, 6262184673, mrosenzweig@coh.org

City of Hope at SeacliffRECRUITING

Huntington Beach, California
Michael Rosenzweig, 6262184673, mrosenzweig@coh.org

City of Hope at South BayRECRUITING

Torrance, California
Michael Rosenzweig, 6262184673, mrosenzweig@coh.org

City of Hope at South PasadenaRECRUITING

South Pasadena, California
MIchael mic Rosenzweig, 6262184673, mrosenzweig@coh.org

City of Hope at UplandRECRUITING

Upland, California
MIchael Rosenzweig, 6262184673, mrosenzweig@coh.org

City of Hope Medical CenterRECRUITING

Duarte, California
Michael A. Rosenzweig, 626-256-4973, mrosenzweig@coh.org

ClinicalTrials.gov record


NCT04508790. First posted on 8/11/20

Call center employee on the phone offering help to a caller

Questions? Contact our Clinical Trials Navigator

1-888-814-8610
contact@ctsearchsupport.org